Synthesis, Biological Evaluation, and Molecular Modeling Study of Substituted Benzyl Benzamides as CETP Inhibitors

Arch Pharm (Weinheim). 2017 Dec;350(12). doi: 10.1002/ardp.201700204. Epub 2017 Nov 7.

Abstract

Cardiovascular disease is the most common cause for mortality and morbidity in the developed world; its risk is inversely related to the high-density lipoprotein (HDL) cholesterol levels. Therefore, there is a great interest in developing new cholesteryl ester transfer protein (CETP) inhibitors capable of raising HDL as a novel approach for the prevention of cardiovascular disease. Herein, the synthesis and characterization of ten benzyl benzamides 8a-j that aim at CETP inhibition was performed. The in vitro CETP inhibition bioassay revealed that benzamide 8j had the best activity, with a percent inhibition of 82.2% at 10 μM concentration and an IC50 value of 1.3 μM. The docking study shows that the verified compounds accommodate the binding cleft of CETP and are enclosed by a hydrophobic lining. Furthermore, the scaffold of 8a-j matches the pharmacophoric points of CETP inhibitors, particularly in its hydrophobic and aromatic functionalities.

Keywords: Atherosclerosis; Benzyl benzamides; CETP inhibitors; Docking; Pharmacophore mapping.

MeSH terms

  • Anticholesteremic Agents / chemical synthesis
  • Anticholesteremic Agents / chemistry
  • Anticholesteremic Agents / pharmacology*
  • Benzamides / chemical synthesis
  • Benzamides / chemistry
  • Benzamides / pharmacology*
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control
  • Cholesterol Ester Transfer Proteins / antagonists & inhibitors*
  • Cholesterol, HDL / blood
  • Drug Design
  • Humans
  • Hydrophobic and Hydrophilic Interactions
  • Inhibitory Concentration 50
  • Models, Molecular*
  • Molecular Docking Simulation
  • Structure-Activity Relationship

Substances

  • Anticholesteremic Agents
  • Benzamides
  • CETP protein, human
  • Cholesterol Ester Transfer Proteins
  • Cholesterol, HDL